FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381094889> ?p ?o ?g. }

• W4381094889 endingPage "1873" @default.
• W4381094889 startingPage "1861" @default.
• W4381094889 abstract "Bamlanivimab and etesevimab (BAM + ETE) are monoclonal antibodies (mAbs) effective in reducing COVID-19-related hospitalizations and all-cause mortality in adult participants at increased risk for severe disease. We present pharmacokinetic (PK), efficacy, and safety results from pediatric participants (< 18 years of age) with COVID-19 who were treated with BAM + ETE.In an addendum to the phase 2/3 BLAZE-1 clinical trial (NCT04427501), pediatric participants received open-label weight-based dosing (WBD, n = 94) based on exposure-matching to the authorized dose of BAM + ETE in adult participants. For efficacy and safety assessments, placebo (n = 14) and BAM + ETE (n = 20)-treated adolescent participants (> 12 to < 18 years of age) from the BLAZE-1 trial were included in the overall pediatric population (N = 128). All participants had mild to moderate COVID-19 upon enrollment and ≥ 1 risk factor for severe COVID-19. The primary objective was to characterize the PK of BAM and ETE in the WBD population.The median age of the participants was 11.2 years, 46.1% were female, 57.9% were Black/African American, and 19.7% were Hispanic/Latino. The area under the curve for BAM and ETE in the WBD population was similar to that previously observed in adults. There were no COVID-19-related hospitalizations or deaths. All adverse events (AE) except one were mild or moderate, with one participant reporting a serious AE.WBD in pediatric participants achieved similar drug exposures compared to adult participants that received the authorized BAM + ETE dose. The pediatric efficacy and safety data were consistent with adults receiving mAbs for COVID-19.NCT04427501." @default.
• W4381094889 created "2023-06-18" @default.
• W4381094889 creator A5002687453 @default.
• W4381094889 creator A5004455987 @default.
• W4381094889 creator A5004522040 @default.
• W4381094889 creator A5005174617 @default.
• W4381094889 creator A5006859484 @default.
• W4381094889 creator A5008101415 @default.
• W4381094889 creator A5011913674 @default.
• W4381094889 creator A5013429688 @default.
• W4381094889 creator A5015497968 @default.
• W4381094889 creator A5016660645 @default.
• W4381094889 creator A5025090895 @default.
• W4381094889 creator A5025715364 @default.
• W4381094889 creator A5025776157 @default.
• W4381094889 creator A5025877100 @default.
• W4381094889 creator A5030424602 @default.
• W4381094889 creator A5030604404 @default.
• W4381094889 creator A5032261051 @default.
• W4381094889 creator A5032668999 @default.
• W4381094889 creator A5036160301 @default.
• W4381094889 creator A5036787987 @default.
• W4381094889 creator A5040618859 @default.
• W4381094889 creator A5041092760 @default.
• W4381094889 creator A5041686566 @default.
• W4381094889 creator A5046763283 @default.
• W4381094889 creator A5046966487 @default.
• W4381094889 creator A5047777011 @default.
• W4381094889 creator A5047922681 @default.
• W4381094889 creator A5048940397 @default.
• W4381094889 creator A5050019087 @default.
• W4381094889 creator A5050373267 @default.
• W4381094889 creator A5054925115 @default.
• W4381094889 creator A5055671933 @default.
• W4381094889 creator A5058013247 @default.
• W4381094889 creator A5058246213 @default.
• W4381094889 creator A5061679177 @default.
• W4381094889 creator A5062643522 @default.
• W4381094889 creator A5064227028 @default.
• W4381094889 creator A5069865054 @default.
• W4381094889 creator A5071474772 @default.
• W4381094889 creator A5074285951 @default.
• W4381094889 creator A5075837693 @default.
• W4381094889 creator A5076109254 @default.
• W4381094889 creator A5076176304 @default.
• W4381094889 creator A5076756685 @default.
• W4381094889 creator A5077415127 @default.
• W4381094889 creator A5078156253 @default.
• W4381094889 creator A5081140079 @default.
• W4381094889 creator A5081267484 @default.
• W4381094889 creator A5083402039 @default.
• W4381094889 creator A5087119214 @default.
• W4381094889 creator A5091292204 @default.
• W4381094889 creator A5091346906 @default.
• W4381094889 creator A5092194938 @default.
• W4381094889 date "2023-06-17" @default.
• W4381094889 modified "2023-10-06" @default.
• W4381094889 title "Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 Trial" @default.
• W4381094889 cites W2091277908 @default.
• W4381094889 cites W2119332183 @default.
• W4381094889 cites W3011307261 @default.
• W4381094889 cites W3011976215 @default.
• W4381094889 cites W3037998048 @default.
• W4381094889 cites W3125712166 @default.
• W4381094889 cites W3167287181 @default.
• W4381094889 cites W3172617797 @default.
• W4381094889 cites W3180301457 @default.
• W4381094889 cites W3195173464 @default.
• W4381094889 cites W3197266611 @default.
• W4381094889 cites W3209238777 @default.
• W4381094889 cites W4200391585 @default.
• W4381094889 cites W4212988737 @default.
• W4381094889 doi "https://doi.org/10.1007/s40121-023-00832-y" @default.
• W4381094889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37329415" @default.
• W4381094889 hasPublicationYear "2023" @default.
• W4381094889 type Work @default.
• W4381094889 citedByCount "1" @default.
• W4381094889 countsByYear W43810948892023 @default.
• W4381094889 crossrefType "journal-article" @default.
• W4381094889 hasAuthorship W4381094889A5002687453 @default.
• W4381094889 hasAuthorship W4381094889A5004455987 @default.
• W4381094889 hasAuthorship W4381094889A5004522040 @default.
• W4381094889 hasAuthorship W4381094889A5005174617 @default.
• W4381094889 hasAuthorship W4381094889A5006859484 @default.
• W4381094889 hasAuthorship W4381094889A5008101415 @default.
• W4381094889 hasAuthorship W4381094889A5011913674 @default.
• W4381094889 hasAuthorship W4381094889A5013429688 @default.
• W4381094889 hasAuthorship W4381094889A5015497968 @default.
• W4381094889 hasAuthorship W4381094889A5016660645 @default.
• W4381094889 hasAuthorship W4381094889A5025090895 @default.
• W4381094889 hasAuthorship W4381094889A5025715364 @default.
• W4381094889 hasAuthorship W4381094889A5025776157 @default.
• W4381094889 hasAuthorship W4381094889A5025877100 @default.
• W4381094889 hasAuthorship W4381094889A5030424602 @default.
• W4381094889 hasAuthorship W4381094889A5030604404 @default.
• W4381094889 hasAuthorship W4381094889A5032261051 @default.
• W4381094889 hasAuthorship W4381094889A5032668999 @default.
• W4381094889 hasAuthorship W4381094889A5036160301 @default.

• next